New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer

(marketscreener.com) – Late-Breaking TROPiCS-02 Analysis Shows that Trodelvy Demonstrates Consistent Efficacy Across Trop-2 Expression Levels –– Trop-2 is Highly Expressed in 90% of Breast Cancers –– Trodelvy is Currently Under Priority Review with the U.S. FDA for Pre-Treated HR+/HER2- Metastatic Breast Cancer –https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/New-Data-for-Trodelvy-Demonstrate-Clinical-Efficacy-Across-Trop-2-Expression-Levels-in-HR-HER2-Met-42489460/?utm_medium=RSS&utm_content=20221206